학술논문
Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh.
Document Type
Academic Journal
Author
Jamiruddin R; Department of Pharmacy, Brac University, Dhaka, Bangladesh.; Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka, Bangladesh.; Haq A; Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka, Bangladesh.; Khondoker MU; Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka, Bangladesh.; Department of Community Medicine, Gonoshasthaya Samaj Vittik Medical College, Savar, Dhaka, Bangladesh.; Ali T; Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka, Bangladesh.; Ahmed F Md; Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh.; Khandker SS; Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka, Bangladesh.; Jawad I; Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh.; Hossain R; Department of Microbiology, Gono Bishwabidyalay, Savar, Dhaka, Bangladesh.; Ahmed S; Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka, Bangladesh.; Rahman SR; Department of Microbiology, University of Dhaka, Dhaka, Bangladesh.; Mustafi M; Department of Community Medicine, Gonoshasthaya Samaj Vittik Medical College, Savar, Dhaka, Bangladesh.; Kaitsuka T; Department of Pharmaceutical Sciences, School of Pharmacy, International University of Health and Welfare, Okawa, Fukuoka, Japan.; Mie M; School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Kanagawa, Japan.; Tomizawa K; Department of Molecular Physiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.; Kobatake E; School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Kanagawa, Japan.; Haque M; The Unit of Pharmacology, Faculty of Medicine and Defence Health Universiti Pertahanan, Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sugai Besi, Kuala Lumpur, Malaysia.; Adnan N; Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka, Bangladesh.; Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh.
Source
Publisher: Taylor & Francis Country of Publication: England NLM ID: 101155475 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8395 (Electronic) Linking ISSN: 14760584 NLM ISO Abbreviation: Expert Rev Vaccines Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Vaccination with the Oxford-AstraZeneca COVID-19 vaccine (AZD1222) initially started in the UK and quickly implemented around the Globe, including Bangladesh. Up to date, more than nine million doses administrated to the Bangladeshi public.
Method: Herein, we studied the antibody response to the first dose of AZD1222 in 86 Bangladeshi individuals using in-house ELISA kits. Study subjects were categorized into two groups, convalescent and uninfected, based on prior infection history and SARS-CoV-2 nucleocapsid-IgG profiles.
Results: All the convalescent individuals presented elevated spike-1-IgG compared to 90% of uninfected ones after the first dose. Day >28 post-vaccination, the convalescent group showed six times higher antibody titer than the uninfected ones. The most elevated antibody titers for the former and later group were found at Day 14 and Days >28 post-vaccination, respectively. The spike-1-IgA titer showed a similar pattern as spike-1-IgG, although in a low-titer. In contrast, the IgM titer did not show any significant change in either group.
Conclusion: High antibody titer in the convalescent group, signify the importance of the first dose among the uninfected group. This study advocates the integration of antibody tests in vaccination programs in the healthcare system for maximizing benefit.
Method: Herein, we studied the antibody response to the first dose of AZD1222 in 86 Bangladeshi individuals using in-house ELISA kits. Study subjects were categorized into two groups, convalescent and uninfected, based on prior infection history and SARS-CoV-2 nucleocapsid-IgG profiles.
Results: All the convalescent individuals presented elevated spike-1-IgG compared to 90% of uninfected ones after the first dose. Day >28 post-vaccination, the convalescent group showed six times higher antibody titer than the uninfected ones. The most elevated antibody titers for the former and later group were found at Day 14 and Days >28 post-vaccination, respectively. The spike-1-IgA titer showed a similar pattern as spike-1-IgG, although in a low-titer. In contrast, the IgM titer did not show any significant change in either group.
Conclusion: High antibody titer in the convalescent group, signify the importance of the first dose among the uninfected group. This study advocates the integration of antibody tests in vaccination programs in the healthcare system for maximizing benefit.